Pharmacologic evaluation of ospemifene

Jamie L. Mccall, Michael W. Degregorio

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Importance of the field: Millions of women worldwide suffer from vulvovaginal atrophy (VVA) associated with menopause, and many women report that this adversely affects their quality of life. Ospemifene is a non-hormonal estrogen receptor agonist/antagonist effective in the treatment of VVA. Although similar in structure to other estrogen receptor agonists/antagonists that have antagonistic effects on the vagina, ospemifene has an estrogen-like effect on vaginal epithelium. This review focuses on ospemifene including its pharmacologic properties, clinical efficacy and safety. Areas covered in this review: The paper provides information on the phamacodynamic and pharmacokinetic properties of ospemifene. It also contains an overview of its preclinical and clinical efficacy as well as its clinical safety. What the reader will gain: From this paper, the reader will gain an appreciation for a new non-hormonal estrogen receptor agonist/antagonist, ospemifene. Take home message: The pharmacologic properties of ospemifene make it a logical candidate for the treatment of women with moderate to severe symptoms of VVA associated with menopause. Clinical trials have confirmed that daily doses are well-tolerated and that it is effective in normalizing vaginal maturation index and pH as well as improving the symptoms associated with VVA including dyspareunia.

Original languageEnglish (US)
Pages (from-to)773-779
Number of pages7
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume6
Issue number6
DOIs
StatePublished - 2010

Fingerprint

Atrophy
Estrogens
Menopause
Dyspareunia
Safety
Pharmacokinetics
Vagina
Ospemifene
Epithelium
Quality of Life
Clinical Trials
Therapeutics
Estrogen Receptor Antagonists

Keywords

  • Dyspareunia
  • Non-hormonal estrogen receptor agonist/antagonist
  • Ospemifene
  • Vulvovaginal atrophy

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Medicine(all)

Cite this

Pharmacologic evaluation of ospemifene. / Mccall, Jamie L.; Degregorio, Michael W.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 6, No. 6, 2010, p. 773-779.

Research output: Contribution to journalArticle

Mccall, Jamie L. ; Degregorio, Michael W. / Pharmacologic evaluation of ospemifene. In: Expert Opinion on Drug Metabolism and Toxicology. 2010 ; Vol. 6, No. 6. pp. 773-779.
@article{9e019c336ed1471989fde7535cd5cec9,
title = "Pharmacologic evaluation of ospemifene",
abstract = "Importance of the field: Millions of women worldwide suffer from vulvovaginal atrophy (VVA) associated with menopause, and many women report that this adversely affects their quality of life. Ospemifene is a non-hormonal estrogen receptor agonist/antagonist effective in the treatment of VVA. Although similar in structure to other estrogen receptor agonists/antagonists that have antagonistic effects on the vagina, ospemifene has an estrogen-like effect on vaginal epithelium. This review focuses on ospemifene including its pharmacologic properties, clinical efficacy and safety. Areas covered in this review: The paper provides information on the phamacodynamic and pharmacokinetic properties of ospemifene. It also contains an overview of its preclinical and clinical efficacy as well as its clinical safety. What the reader will gain: From this paper, the reader will gain an appreciation for a new non-hormonal estrogen receptor agonist/antagonist, ospemifene. Take home message: The pharmacologic properties of ospemifene make it a logical candidate for the treatment of women with moderate to severe symptoms of VVA associated with menopause. Clinical trials have confirmed that daily doses are well-tolerated and that it is effective in normalizing vaginal maturation index and pH as well as improving the symptoms associated with VVA including dyspareunia.",
keywords = "Dyspareunia, Non-hormonal estrogen receptor agonist/antagonist, Ospemifene, Vulvovaginal atrophy",
author = "Mccall, {Jamie L.} and Degregorio, {Michael W.}",
year = "2010",
doi = "10.1517/17425255.2010.487483",
language = "English (US)",
volume = "6",
pages = "773--779",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Pharmacologic evaluation of ospemifene

AU - Mccall, Jamie L.

AU - Degregorio, Michael W.

PY - 2010

Y1 - 2010

N2 - Importance of the field: Millions of women worldwide suffer from vulvovaginal atrophy (VVA) associated with menopause, and many women report that this adversely affects their quality of life. Ospemifene is a non-hormonal estrogen receptor agonist/antagonist effective in the treatment of VVA. Although similar in structure to other estrogen receptor agonists/antagonists that have antagonistic effects on the vagina, ospemifene has an estrogen-like effect on vaginal epithelium. This review focuses on ospemifene including its pharmacologic properties, clinical efficacy and safety. Areas covered in this review: The paper provides information on the phamacodynamic and pharmacokinetic properties of ospemifene. It also contains an overview of its preclinical and clinical efficacy as well as its clinical safety. What the reader will gain: From this paper, the reader will gain an appreciation for a new non-hormonal estrogen receptor agonist/antagonist, ospemifene. Take home message: The pharmacologic properties of ospemifene make it a logical candidate for the treatment of women with moderate to severe symptoms of VVA associated with menopause. Clinical trials have confirmed that daily doses are well-tolerated and that it is effective in normalizing vaginal maturation index and pH as well as improving the symptoms associated with VVA including dyspareunia.

AB - Importance of the field: Millions of women worldwide suffer from vulvovaginal atrophy (VVA) associated with menopause, and many women report that this adversely affects their quality of life. Ospemifene is a non-hormonal estrogen receptor agonist/antagonist effective in the treatment of VVA. Although similar in structure to other estrogen receptor agonists/antagonists that have antagonistic effects on the vagina, ospemifene has an estrogen-like effect on vaginal epithelium. This review focuses on ospemifene including its pharmacologic properties, clinical efficacy and safety. Areas covered in this review: The paper provides information on the phamacodynamic and pharmacokinetic properties of ospemifene. It also contains an overview of its preclinical and clinical efficacy as well as its clinical safety. What the reader will gain: From this paper, the reader will gain an appreciation for a new non-hormonal estrogen receptor agonist/antagonist, ospemifene. Take home message: The pharmacologic properties of ospemifene make it a logical candidate for the treatment of women with moderate to severe symptoms of VVA associated with menopause. Clinical trials have confirmed that daily doses are well-tolerated and that it is effective in normalizing vaginal maturation index and pH as well as improving the symptoms associated with VVA including dyspareunia.

KW - Dyspareunia

KW - Non-hormonal estrogen receptor agonist/antagonist

KW - Ospemifene

KW - Vulvovaginal atrophy

UR - http://www.scopus.com/inward/record.url?scp=77952518682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952518682&partnerID=8YFLogxK

U2 - 10.1517/17425255.2010.487483

DO - 10.1517/17425255.2010.487483

M3 - Article

VL - 6

SP - 773

EP - 779

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 6

ER -